Furmonertinib is an oral, highly brain-penetrant, broadly active mutation-selective EGFR inhibitor that targets both classical (exon 19 deletion and L858R) and uncommon EGFR mutations, including exon 20 insertion mutations as well as HER2 exon 20 insertion mutations.
ArriVent is studying furmonertinib globally in patients with NSCLC with EGFR mutations. To learn more about these clinical studies, please select from below.
First-line Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer With Activating EGFR or HER2 Mutations